· Venture Capital Tracker Editorial · investment-strategies
Enveda Closes $311M Series E for AI-Discovered Medicines
Enveda closed a $311 million Series E led by Catalio Capital Management to advance nature-derived drug candidates and expand its AI discovery platform. The company has now disclosed more than $845 million in funding.
Enveda closed a $311 million Series E on September 23, 2026, led by Catalio Capital Management. The financing takes the clinical-stage biotechnology company’s disclosed funding above $845 million.
New investors included Durable Capital Partners, ICONIQ, Lightspeed, Surveyor Capital, accounts advised by T. Rowe Price Investment Management, Digitalis Ventures and an unnamed sovereign fund. Alderline Group also joined, while Baillie Gifford, Premji Invest, FPV, True Ventures, Kinnevik, Dimension, Lifeforce Capital and Lux Capital returned.
Deal terms
| Field | Detail |
|---|---|
| Company | Enveda |
| Financing | $311M Series E |
| Lead | Catalio Capital Management |
| Total disclosed funding | More than $845M |
| Status | Company-announced close |
| Valuation | Not disclosed by Enveda |
From discovery platform to clinical execution
Enveda uses machine learning to analyse the chemistry found in plants and other biological sources, then turns selected molecules into drug candidates. The Series E is therefore less about proving that AI can generate hypotheses and more about financing expensive clinical development.
That distinction matters. Many AI-biotechnology companies are valued on platform potential before a candidate reaches patients. Enveda already has clinical-stage programs, so the next milestones are conventional biotechnology milestones: safety, dosing, efficacy signals and the ability to run several programs without allowing costs to outpace evidence.
The company said the new capital will advance programs in inflammation and obesity-related weight maintenance while continuing to develop its discovery platform. Those uses give the round both a pipeline component and an infrastructure component.
What remains unknown
Enveda did not disclose its valuation, the ownership sold, or expected runway. Reported valuations should not be treated as company-confirmed terms. The broad syndicate also does not reveal how much each investor committed.
The scientific claims still need the same scrutiny applied to any clinical-stage biotechnology company. AI can help prioritize molecules, but it does not remove toxicology, manufacturing, regulatory or trial risk.
Bottom line
The financing is a confirmed $311 million Series E, not an acquisition, debt facility or grant. Its significance will be determined by whether Enveda can convert a large natural-products data advantage into reproducible human clinical results.
Follow Venture Capital Tracker in Google
Add VCT as a preferred source to make our venture-capital coverage easier to find in Google Search.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.